Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Rating of “Hold” from Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN) has earned an average rating of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $35.75.

SNN has been the topic of a number of recent research reports. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 10th. Finally, Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a research report on Tuesday, October 14th.

Smith & Nephew SNATS Price Performance

SNN opened at $32.92 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The company’s 50 day simple moving average is $32.97 and its 200-day simple moving average is $34.25. Smith & Nephew SNATS has a one year low of $23.91 and a one year high of $38.79.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Smith & Nephew SNATS by 11.7% in the 3rd quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 401 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Smith & Nephew SNATS by 5.0% during the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock worth $323,000 after buying an additional 423 shares during the last quarter. Vise Technologies Inc. grew its position in shares of Smith & Nephew SNATS by 4.7% during the 3rd quarter. Vise Technologies Inc. now owns 9,642 shares of the medical equipment provider’s stock worth $350,000 after buying an additional 437 shares during the period. Quadrant Capital Group LLC increased its stake in shares of Smith & Nephew SNATS by 3.6% in the 3rd quarter. Quadrant Capital Group LLC now owns 12,757 shares of the medical equipment provider’s stock valued at $463,000 after acquiring an additional 440 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Smith & Nephew SNATS by 4.6% in the 3rd quarter. First Trust Advisors LP now owns 10,532 shares of the medical equipment provider’s stock valued at $382,000 after acquiring an additional 459 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.